cp wire

CP Wire Articles

Sirnaomics Inc. announced on 4/26/19 that it has sealed the C2 round of financing for $22 million. This round of funding was led by CR-CP Life Sciences Fund, a Hong Kong based joint venture... read more

Fri, 04/26/19 - 10:01 am

Clinical-stage biopharma, Applied Therapeutics, updated the filing for its upcoming IPO. The company will raise up to $86 million. It intends to trade under the symbol, "APLT", on NASDAQ.

... read more

Thu, 04/25/19 - 09:42 am

On 4/22/19, Gritstone Oncology filed for a $102 Million offering of its common stock. Gritstone trades on NASDAQ under the symbol, “GRTS.” The company currently has a market cap of $394 Million.... read more

Tue, 04/23/19 - 09:45 am

On 4/22/19, TransMedics updated their filing for an IPO to raise up to $91 million. The commercial stage company has developed an organ transplant support system for heart, lung and liver... read more

Mon, 04/22/19 - 10:08 am

Clinical stage biopharmaceutical company, Trevi Therapeutics, updated their filing for an IPO to raise up to $74 million. Trevi is focused on the development and commercialization of nalbuphine ER... read more

Mon, 04/22/19 - 09:49 am

On 4/17/19 KCI Holdings filed for a $100 million IPO. KCI is a leading medical technology company focused on advanced wound care and specialty surgical applications. The initial filing did not... read more

Thu, 04/18/19 - 10:00 am

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ:  EVGN) (TASE: EVGN), announced on 4/17/19 the... read more

Wed, 04/17/19 - 09:44 am

 On 4/16/19, Flagship Pioneering,  unveiled Kintai Therapeutics and named Paul-Peter Tak, M.D., Ph.D., as president, chief executive officer, and member of the board of directors. Kintai is... read more

Tue, 04/16/19 - 09:54 am

Cortexyme has filed for an $86 million IPO. The company is developing treatments for neurodegenerative diseases based on the discovery of pathogenic bacteria in the brains of Alzheimer's patients... read more

Mon, 04/15/19 - 09:56 am

Early stage biotech, Axcella Health, has filed for an $86 million IPO. The initial filing documents do not provide the number of shares in the offering or the expected price range. The company has... read more

Fri, 04/12/19 - 09:46 am

MaaT Pharma announced on 4/9/19 that the independent Data and Safety Monitoring Board (DSMB) recommended the continuation, without amendment, of the ongoing Phase II HERACLES study (NCT03359980).... read more

Wed, 04/10/19 - 09:24 pm

On 4/8/19 researchers from Azitra, Inc., in collaboration withindependent, nonprofit biomedical research institutionThe Jackson Laboratory (JAX), announced they have demonstrated the feasibility... read more

Wed, 04/10/19 - 08:12 pm

OZ, a global consulting company enhancing customer experiences through digital innovation, recently launched a first-of-its-kind application that brings an augmented reality (AR) environment to... read more

Wed, 04/10/19 - 09:35 am

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, Provided  the results of its first human study on 4/8/19.

The study was primarily undertaken to show... read more

Mon, 04/8/19 - 09:54 am

Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, updated its S-1 Filing. The company is proposing... read more

Mon, 04/8/19 - 09:40 am
RENNES, FRANCE — DIAFIR, a medical technology company focused on the development, manufacture and sale of innovative diagnostic solutions... read more
Mon, 04/8/19 - 12:18 am

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) announced on 4/5/19 that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid... read more

Fri, 04/5/19 - 10:44 am


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.